![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Valeant CEO to Meet With Senate, Avoid Contempt Citation
Valeant CEO to Meet With Senate, Avoid Contempt Citation
April 19, 2016
It took a few days and a threatened contempt of Congress citation, but Valeant Pharmaceuticals International’s CEO J. Michael Pearson has agreed to meet with Senate officials investigating rising prescription drug prices.
Valeant’s outgoing CEO is scheduled to be deposed April 18 by the Senate Special Committee on Aging after failing to show for a scheduled deposition last week, according to the committee. Pearson, who has been at the center of a firestorm over pharmaceutical pricing after Valeant raised the price of one drug 500 percent last fall, is under subpoena to appear before the committee April 27.
Upcoming Events
-
21Oct